The Latest Cardiac and Vascular News
MARLBOROUGH, Mass., May 9, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems. The approval includes new features in the Resonate devices including SmartCRT technology with Multisite Pacing […]
MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago on May 10-13. Notably, the post-market approval data collected on […]
MARLBOROUGH, Mass., April 27, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.160 billion during the first quarter ended March 31, 2017. This represents growth of 10 percent compared to the prior year period on a reported and operational basis (calculated on a constant currency basis). The company reported […]
MARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, for $435 million in up-front cash. The Symetis portfolio includes the ACURATE TA™ and ACURATE neo/TF valve* […]
